Evidence map›Paper›PMID 35106623›Full record

ArticleCell and tissue research2022

Effect of expansion of human umbilical cord blood CD34 + cells on neurotrophic and angiogenic factor expression and function.

Ashalyn P Watt, Mark Kirkland, Lakshmi Nekkanti, Yen Pham, Courtney McDonald, Atul Malhotra, Guy Moeneclaey, Suzanne L Miller, Graham Jenkin

Open access · hybridAbstract read
In one paragraph

Article in Cell and tissue research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ashalyn P WattThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia. ashalyn.watt@monash.edu.ORCID http://orcid.org/0000-0001-5588-6935
Mark KirklandCell Care Australia, Heatherton, VIC, Australia.
Lakshmi NekkantiThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Yen PhamThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Courtney McDonaldThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Atul MalhotraThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Guy MoeneclaeyThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Suzanne L MillerThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Graham JenkinThe Ritchie Centre, Hudson Institute of Medical Research, Clayton, VIC, Australia.
Hudson Institute of Medical Research · AUDeakin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of CD34 + cell-based therapies has largely been focused on haematological conditions. However, there is increasing evidence that umbilical cord blood (UCB) CD34 + -derived cells have neuroregenerative properties. Due to low cell numbers of CD34 + cells present in UCB, expansion is required to produce sufficient cells for therapeutic purposes, especially in adults or when frequent applications are required. However, it is not known whether expansion of CD34 + cells has an impact on their function and neuroregenerative capacity. We addressed this knowledge gap in this study, via expansion of UCB-derived CD34 + cells using combinations of LDL, UM171 and SR-1 to yield large numbers of cells and then tested their functionality. CD34 + cells expanded for 14 days in media containing UM171 and SR-1 resulted in over 1000-fold expansion. The expanded cells showed an up-regulation of the neurotrophic factor genes BDNF, GDNF, NTF-3 and NTF-4, as well as the angiogenic factors VEGF and ANG. In vitro functionality testing showed that these expanded cells promoted angiogenesis and, in brain glial cells, promoted cell proliferation and reduced production of reactive oxygen species (ROS) during oxidative stress. Collectively, this study showed that our 14-day expansion protocol provided a robust expansion that could produce enough cells for therapeutic purposes. These expanded cells, when tested in in vitro, maintained functionality as demonstrated through promotion of cell proliferation, attenuation of ROS production caused by oxidative stress and promotion of angiogenesis.

Indexed as

Angiogenesis Inducing AgentsFetal BloodAdultAntigens, CD34Cell ProliferationCells, CulturedHumansAngiogenesis Inducing AgentsAntigens, CD34AngiogenesisCD34Cell expansionHaematopoietic stem cellsNeurotrophins

Identifiers

PMID35106623
PMCPMC8976778
OpenAlexW4210400294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.